These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10066888)

  • 1. Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer.
    Njar VC; Brodie AM
    Curr Pharm Des; 1999 Mar; 5(3):163-80. PubMed ID: 10066888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP17 inhibitors for prostate cancer therapy.
    Vasaitis TS; Bruno RD; Njar VC
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):23-31. PubMed ID: 21092758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
    Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
    Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CYP17: established and novel approaches in prostate cancer.
    Yap TA; Carden CP; Attard G; de Bono JS
    Curr Opin Pharmacol; 2008 Aug; 8(4):449-57. PubMed ID: 18619560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.
    Salvador JA; Pinto RM; Silvestre SM
    J Steroid Biochem Mol Biol; 2013 Sep; 137():199-222. PubMed ID: 23688836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of CYP 17, a new strategy for the treatment of prostate cancer.
    Hartmann RW; Ehmer PB; Haidar S; Hector M; Jose J; Klein CD; Seidel SB; Sergejew TF; Wachall BG; Wächter GA; Zhuang Y
    Arch Pharm (Weinheim); 2002 Apr; 335(4):119-28. PubMed ID: 12112031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
    Bird IM; Abbott DH
    J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP17 inhibitors for prostate cancer treatment--an update.
    Moreira VM; Salvador JA; Vasaitis TS; Njar VC
    Curr Med Chem; 2008; 15(9):868-99. PubMed ID: 18473796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review.
    Owen CP
    Anticancer Agents Med Chem; 2009 Jul; 9(6):613-26. PubMed ID: 19601745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
    Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
    Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
    Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
    Vasaitis T; Belosay A; Schayowitz A; Khandelwal A; Chopra P; Gediya LK; Guo Z; Fang HB; Njar VC; Brodie AM
    Mol Cancer Ther; 2008 Aug; 7(8):2348-57. PubMed ID: 18723482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P450-dependent enzymes as targets for prostate cancer therapy.
    De Coster R; Wouters W; Bruynseels J
    J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.
    Haidar S; Hartmann RW
    Pharmazie; 2017 Sep; 72(9):529-536. PubMed ID: 29441980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
    Yin L; Hu Q
    Nat Rev Urol; 2014 Jan; 11(1):32-42. PubMed ID: 24276076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.
    Nnane IP; Kato K; Liu Y; Long BJ; Lu Q; Wang X; Ling YZ; Brodie A
    Endocrinology; 1999 Jun; 140(6):2891-7. PubMed ID: 10342882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
    Gianti E; Zauhar RJ
    J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
    Grigoryev DN; Long BJ; Nnane IP; Njar VC; Liu Y; Brodie AM
    Br J Cancer; 1999 Oct; 81(4):622-30. PubMed ID: 10574247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.
    Zhu H; Garcia JA
    Curr Oncol Rep; 2013 Apr; 15(2):105-12. PubMed ID: 23371447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the potential of polyphenols as a CYP17 inhibitor free of adverse corticosteroid elevation.
    Lin CJ; Cheng LC; Lin TC; Wang CJ; Li LA
    Biochem Pharmacol; 2014 Aug; 90(3):288-96. PubMed ID: 24875446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.